Stay updated with breaking news from Development Highlights. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Half Year Results Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
25.08.2022 - Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand ...
/PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported...
Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the...